[Comparison of the variations in the levels of beta2-microglobulin and carcino-embryonic antigen in the breast cancer and malignant melanoma (author's transl)].
A variety of markers have been used in the surveillance of carcinoma of the breast and malignant melanoma, including carcino-embryonic antigen (CEA) beta2-microglobulin (beta2m) and prolactin. The dual purpose of the surveillance was the detection of early recurrence or metastasis and the monitoring of the treatment. In cancer of the breast 92% of patients having bone metastases have elevated levels of CEA or beta2m. In malignant melanoma 2/3 of the patients in relapse have elevated beta2m levels.